Now I have enough to write a comprehensive preview. Let me pull one more piece — recent stock price context and consensus data summary — then compose the report.# Altria Group (MO) — Q2 2026 Earnings Preview Report Date: Thursday, July 30, 2026 (before market open) | Call: 9:00 AM ET
Altria enters tomorrow's report on a strong run: the stock has climbed from the high-$50s in January to roughly $75 today, sitting near 52-week highs and outperforming the broader market. Analysts are looking for Q2 adjusted EPS of ~$1.50 (up ~4.2% y/y from $1.44) on revenue of roughly $5.36 billion (up ~1.1–1.4% y/y). Notably, the average sell-side price target (~$70–71) sits below the current share price — the market has already priced in a fair amount of good news, which raises the bar for tomorrow's results and any full-year guidance commentary.
Q1 was a "beat and reaffirm" quarter that reset expectations for the year. Altria delivered a strong start to the year, growing adjusted diluted EPS by 7.3% in the first quarter, with adjusted diluted EPS increased 7.3% to $1.32, driven by higher adjusted OCI and fewer shares outstanding. Smokeables were the standout: segment adjusted OCI grew by 6.3% with adjusted OCI margins expanding to 65.1%, an increase of 0.7 percentage points... supported by solid net price realization of 6.3%, and management noted that the decline in our smokeable volumes continue to moderate — industry cigarette volumes were down an estimated 5%, marking the fourth consecutive quarter of sequential year-over-year moderation, which the company attributed to reduced cross-category movement between cigarettes and illicit flavored disposable e-vapor products.
Management reaffirmed full-year 2026 guidance of $5.56–$5.72 adjusted EPS (2.5%–5.5% growth off a $5.42 base) but flagged that as a result of the strong first quarter performance, we now expect 2026 adjusted diluted EPS growth to be more balanced between the first half and the second half of the year — a shift from the "second-half weighted" framing given back in February. That balance is the key thing tomorrow's print needs to validate.
1. Guidance cadence and possible tightening/raise. With Q1 stronger than expected and consensus implying steady ~4% growth in Q2, investors will want confirmation that the "more balanced" 1H/2H phasing is playing out, and will watch closely for any narrowing or lift to the $5.56–$5.72 range — something management notably declined to do in Q1 despite the beat, citing macro uncertainty.
2. Smokeable trade-down dynamics. In Q1, this trade down dynamic impacted Marlboro's overall retail share, which declined 1.4 share points versus the year ago period, even as Marlboro continued to demonstrate its competitive strength in the profitable premium segment, expanding to 59.5% [share] of the premium segment, up 0.1 share point versus the prior year. Meanwhile Basic (discount) has been picking up share via targeted revenue-growth-management promotions. Watch whether discount-segment growth (a function of a still-pressured, price-sensitive smoker) continues, and whether the newly rolled-out Marlboro Cowboy Cut — expanding distribution in Q2 — is gaining traction as a value tool without cannibalizing core Marlboro.
3. Oral tobacco / on! PLUS execution. Helix began shipping on! PLUS nationwide in March, and by quarter-end it was available in approximately 100,000 stores, representing 85% of nicotine pouch category volume. But on!'s share of the fast-growing nicotine-pouch category actually fell 4.2 points to 13.4% in Q1 even as volumes surged on pipeline fill, reflecting intense competition (notably from Zyn). Q2 is the first full quarter of on! PLUS's real retail sell-through, so watch retail share/offtake data rather than shipment volumes, plus updates on FDA authorization progress for additional flavors under the pilot review program.
4. The e-vapor/regulatory wildcard. This is arguably the most important swing factor heading into this print that wasn't fully in play in Q1. In May 2026, the FDA issued a new enforcement-discretion policy that critics argue effectively allows unauthorized flavored e-cigarettes to remain on shelves — a reversal of the tightening enforcement backdrop that had been credited with pushing some smokers back to cigarettes and boosting Altria's combustible volumes. This has drawn Congressional scrutiny (a Senate letter to CEO Sal Mancuso in June 2026) and is a direct threat to the "cross-category moderation" thesis embedded in guidance. Listen for management's updated read on illicit vape supply, whether the favorable volume trends seen in Q1 held up through Q2, and any commentary on NJOY's path back to market — which remains sidelined amid ongoing ITC/JUUL patent litigation (a hearing is scheduled for September 2026 with an initial determination expected in December 2026).
5. Capital returns and the dividend increase. Altria typically announces its annual dividend hike around this time of year — last year's was a 4% increase to $1.06/share (the 60th increase in 56 years), and the stock currently yields roughly 5.8%. Investors will watch for the ~61st consecutive increase alongside earnings. Also watch buyback pace: at Q1-end, we had $720 million remaining under our current share repurchase program, which expires at the end of the year, and leverage remains near target at 1.9x total debt-to-EBITDA.
This is essentially the first full quarter under Altria's new leadership team. This will be my final earnings call as CEO, Billy Gifford said on the Q1 call before formally retiring at the May 14, 2026 Annual Meeting, when Sal Mancuso (former CFO) became CEO and Heather Newman became CFO. Gifford remains a paid consultant through year-end to aid the transition. With Mancuso — the architect of recent guidance and RGM (revenue growth management) strategy — now in the top seat, investors will be listening for any early signals of strategic emphasis shifts, though continuity is the expected base case given his tenure as CFO.
| Metric | Q2 2025 Actual | Q2 2026 Consensus |
|---|---|---|
| Adjusted diluted EPS | $1.44 | ~$1.50 (+4.2% y/y) |
| Net revenue | ~$5.29B | ~$5.36B (+1.1–1.4% y/y) |
| FY26 EPS guidance (reaffirmed in Q1) | — | $5.56–$5.72 (2.5%–5.5% growth) |
Bottom line: Altria heads into this print with momentum, a raised bar from Q1's beat, and a dividend/buyback story that continues to anchor the income thesis. The incremental debate is less about the smokeable/oral core (which has been executing well) and more about whether the recent FDA enforcement shift on flavored vapes threatens the volume-moderation trend that has been driving upside surprises, and whether new CEO Sal Mancuso uses this call to firm up (or raise) full-year guidance.